enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense (approximately 50% of its workforce).
“equity retention awards, which will vest, if at all, upon the achievement of the Milestones, the Company now estimates that it will incur restructuring costs of approximately $5.7 to $6.4 million in cash, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash”
Kathleen Richton was appointed as Senior Vice President, Finance at enGene Therapeutics Inc..
“the Board appointed Kathleen Richton as Senior Vice President, Finance of the Company, with her appointment to become effective on or about July 16, 2026.”
Ryan Daws departed as Chief Financial Officer at enGene Therapeutics Inc..
“the Company announced that its Chief Financial Officer, Ryan Daws, will depart the Company effective July 15, 2026”
Hussein Sweiti resigned as Chief Medical Officer at enGene Therapeutics Inc..
“On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.”
Earnings Releases
enGene Therapeutics Inc. reported financial results for the second quarter ended April 30, 2026.
“enGene Therapeutics Inc. (the “Company”) announced its financial results for the three months ended April 30, 2026”
Restructurings & Charges
enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million affecting the Company (approximately 50%).
“activities required to support the commercial launch of detalimogene in 2027, if approved. The Company currently estimates it will incur restructuring costs of approximately $5.7 to $6.4 million, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash stock-based”
Shareholder Votes
enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2026-06-09 meeting.
“Proposal 2 – Appointment and Remuneration of Auditor For Withhold Broker Non-Votes 56,180,287 16,015 -”
Shareholder Votes
enGene Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.
“Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Philip Astley-Sparke 47,112,414 306,821 8,777,067 Ronald H.W. Cooper 47,329,848 89,387 8,777,067 Dr. William Grossman 47,408,163 11,072 8,777,067 Michael Heffernan 47,408,163 11,072 8,777,067”
Governance Changes
enGene Therapeutics Inc.: Amended Articles to change corporate name from enGene Holdings Inc. to enGene Therapeutics Inc (effective 2026-04-08).
“On April 6, 2026, enGene Therapeutics Inc., formerly known as enGene Holdings Inc. (the “Company”), filed a notice of alteration (the “Notice of Alteration”) with the Province of British Columbia Registrar of Companies to change the Company’s corporate name to enGene Therapeutics Inc., effective as of April 8, 2026 (the “Name Change”).”
Earnings Releases
enGene Therapeutics Inc. reported first quarter ended January 31, 2026 results: net income net loss attributable to common shareholders was approximately $29.8 million, EPS $0.44 per share.
“enGene Reports First Quarter 2026 Financial Results and Provides Business Update”
Material Agreements
enGene Therapeutics Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at terminated Prior Sales Agreement; no shares sold (effective 2026-02-27).
“On February 27, 2026, the Company delivered written notice to Jefferies LLC that effective as of March 6, 2026, the Company terminated the Open Market Sale Agreement SM , dated as of December 20, 2024 (the “Prior Sales Agreement”), that the Company had previously entered into with Jefferies LLC, as sales agent.”
Material Agreements
enGene Therapeutics Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $100,000,000 (effective 2026-03-09).
“On March 9, 2026, enGene Holdings Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may sell its common shares, without par value (the “Common Shares”), from time to time through Leerink Partners.”
Equity Issuances
enGene Therapeutics Inc. issued 40,850 2026 Warrants of warrant to Lenders (Hercules Capital, Inc. and others).
“On the Closing Date, the Company issued to the Lenders an aggregate number of 40,850 2026 Warrants reflecting each Lender’s pro rata commitments under the Amended Loan Agreement in connection with the 2026 Tranche 1 Advance (the “2026 Closing Date Warrants”).”
Debt Financings
enGene Therapeutics Inc. incurred term loan of up to $125 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2030.
“The Amended Loan Agreement provides for up to $125 million available for advances in multiple tranches (the “2026 Term Loans”)”
Debt Financings
enGene Therapeutics Inc. incurred term loan of $25 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2030.
“The Amended Loan Agreement provides for up to $125 million available for advances in multiple tranches (the “2026 Term Loans”), as follows: (i) an initial term loan advance (the “2026 Tranche 1 Advance”) of $25 million to refinance in full the term loans outstanding under the Prior Loan Agreement, which advance was issued to the Borrower on the Closing Date”
Material Agreements
enGene Therapeutics Inc. entered into Second Amendment with Hercules Capital, Inc. valued at up to $125 million (effective 2026-01-20).
“On January 20, 2026 (the “Closing Date”), enGene Holdings Inc. (the “Company”, and together with its subsidiaries enGene Inc. and enGene USA, Inc., collectively, the “Borrower”) entered into a Second Amendment (the “Second Amendment”) to its Amended and Restated Loan and Security Agreement”
Dr. Raj S. Pruthi resigned as Chief Medical Officer at enGene Therapeutics Inc..
“On June 3, 2025, Dr. Raj S. Pruthi notified enGene Holdings Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, with his resignation to be effective as of close of business on June 16, 2025.”
Ronald H.W. Cooper changed role as President at enGene Therapeutics Inc..
“Mr. Ronald H.W. Cooper, assumed the additional title of President”
Alexander Nichols was appointed as Chief Strategy and Operations Officer at enGene Therapeutics Inc..
“Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer”
James Sullivan departed as Chief Scientific Officer at enGene Therapeutics Inc..
“Dr. Sullivan shall depart the Company effective October 31, 2024”
Anthony Cheung was appointed as Chief Scientific Officer at enGene Therapeutics Inc..
“Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer”
Jason D. Hanson resigned as Chief Executive Officer at enGene Therapeutics Inc..
“Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.”
Shareholder Votes
enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2024-05-15 meeting.
“Proposal 3 – Appointment and Renumeration of Auditor For Withhold Broker Non-Votes 28,467,217 - -”
Shareholder Votes
enGene Therapeutics Inc. shareholders approved Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan at the 2024-05-15 meeting.
“Proposal 2 – Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan For Against Abstain Broker Non-Votes 25,623,625 2,586,367 2,515 254,710”
Shareholder Votes
enGene Therapeutics Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
“Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Paul Hastings 28,201,063 11,444 254,710 Wouter Joustra 28,212,507 - 254,710 Lota Zoth 28,212,007 500 254,710”
Earnings Releases
enGene Therapeutics Inc. reported first quarter ended January 31, 2024 results: net income net loss attributable to common shareholders was $10.7 million, or $0.46 per share.
“enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.”
Material Agreements
enGene Therapeutics Inc. entered into Subscription Agreements with the investors named therein valued at approximately $200 million (effective 2024-02-13).
“On February 13, 2024, enGene Holdings Inc. (the “ Company ”) entered into subscription agreements (collectively, the “ Subscription Agreements ”) with the investors named therein (the “ Investors ”), for the private placement (the “ Private Placement ”) of 20,000,000 common shares of the Company (the “ Subscribed Shares ”), at a price of $10.00 per share. The aggregate gross proceeds from the Private Placement are expected to be approximately $200 million, before deducting offering expenses.”
Jason Hanson departed as Chief Executive Officer at enGene Therapeutics Inc..
“Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board”
Earnings Releases
enGene Therapeutics Inc. reported the fiscal year ended October 31, 2023 results: net income $104.7 million, EPS $151.22 per share.
“For the full year 2023, net loss attributable to common shareholders was $104.7 million, or $151.22 per share, compared to $29.0 million, or $44.30 per share, for the same period in 2022.”
Debt Financings
enGene Therapeutics Inc. amended term loan of up to $50 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2028.
“2021 (the “Prior Loan Agreement”), by, among other things, adding the Company as a co-borrower thereunder. The Amended Loan Agreement provides for a term loan facility of up to $50 million available in multiple tranches (the “Term Loan”), as follows: (i) an initial term loan advance (the “Tranche 1 Advance”) that was made on the Closing Date of $22.5 million,”
Material Agreements
enGene Therapeutics Inc. amended Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. valued at up to $50 million (effective 2023-12-22).
“On December 22, 2023 (the “Closing Date”), enGene Holdings Inc. (the “Company”), together with its subsidiaries, enGene Inc. and enGene USA, Inc. (collectively with the Company, on a joint and several basis, the “Borrowers”) entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”), with Hercules Capital, Inc., as agent and lender (“Hercules” or “the Bank”), and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the “Lenders”).”
Lota Zoth was appointed as Class I Director and Audit Committee Chair at enGene Therapeutics Inc..
“On December 18, 2023, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), increased its size from four members to five and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lota Zoth to the Board as a Class I Director of the Board, with a term expiring at the Company’s first annual general meeting following her appointment, or until her successor is duly elected and appointed.”
Ryan Daws was appointed as Chief Financial Officer at enGene Therapeutics Inc..
“On December 13, 2023, Ryan Daws, Chief Financial Officer of enGene Holdings Inc. (the “Company”), entered into an Executive Employment Agreement with enGene USA, Inc. (“enGene USA”), effective as of November 27, 2023 (the “Daws Employment Agreement”).”
Alexandre Grassin departed as principal financial officer and principal accounting officer at enGene Therapeutics Inc..
“Mr. Daws replaced Alexandre Grassin as the Company’s principal financial officer and principal accounting officer.”
Ryan Daws was appointed as Chief Financial Officer and Head of Business Development at enGene Therapeutics Inc..
“On November 27, 2023, Ryan Daws became Chief Financial Officer (“CFO”) and Head of Business Development of enGene Holdings Inc.”
Governance Changes
enGene Therapeutics Inc.: FEAC and New enGene ceased to be shell companies upon closing of business combination (effective 2023-10-31).
“On October 31, 2023, as a result of the consummation of the Business Combination, each of FEAC and New enGene ceased to be a shell company.”
Governance Changes
enGene Therapeutics Inc.: Adopted new Code of Business Conduct and Ethics on October 31, 2023 (effective 2023-10-31).
“on October 31, 2023, New enGene’s board of directors approved and adopted a new Code of Business Conduct and Ethics”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.